Telomerase Structural Biology Reveals How Cells Maintain Chromosome Ends

Telomere maintenance sits at the intersection of aging biology and cancer. Telomerase — a specialized reverse transcriptase ribonucleoprotein (RNP) — counteracts the natural shortening of chromosome ends by processively adding telomeric DNA repeats. When telomerase is insufficiently active, telomeres shorten over successive cell divisions, eventually triggering senescence or apoptosis; this underlies premature aging syndromes such as dyskeratosis congenita and contributes to age-related tissue decline. Conversely, aberrant reactivation of telomerase is a hallmark of approximately 85–90% of human cancers, making it a prime therapeutic target.

This comprehensive 2026 review from Cambridge's MRC Laboratory of Molecular Biology focuses on recent structural biology breakthroughs that have transformed understanding of telomerase architecture and mechanism. The two catalytically essential components — telomerase reverse transcriptase (TERT) and telomerase RNA (TER) — form the enzymatic core, but cellular holoenzymes incorporate numerous additional proteins that assist in assembly, stability, and regulated recruitment to telomeres. The review examines how these factors differ and converge across Tetrahymena thermophila (the classical model), budding yeast Saccharomyces cerevisiae, fission yeast Schizosaccharomyces pombe, and humans.

Recent cryo-electron microscopy studies have been particularly transformative, resolving near-atomic structures of telomerase holoenzymes and capturing different catalytic states. These structures reveal how TERT's fingers, palm, and thumb domains encircle the RNA template and nascent DNA, how the template boundary element of TER enforces fidelity of repeat synthesis, and how translocation — the critical repositioning step that enables processivity — is mechanistically achieved. Species-specific accessory proteins are shown to contact both TERT and TER, explaining how they stabilize the holoenzyme and modulate its activity.

For human telomerase specifically, structural studies have clarified how the H/ACA box proteins (dyskerin, NHP2, NOP10, and GAR1) assemble on the TER scaffold, and how factors such as TCAB1, TPP1, and the shelterin complex mediate recruitment to telomeres. Disease-associated mutations in dyskerin and other H/ACA proteins are now interpretable at the atomic level, providing mechanistic explanations for dyskeratosis congenita and related telomeropathies. Similarly, structures from yeast have illuminated the roles of Est proteins and the Sm/Lsm ring in TER biogenesis and holoenzyme integrity.

The review underscores that while the catalytic core is evolutionarily conserved, the peripheral protein machinery diverges substantially across species, reflecting adaptations in telomere biology. These structural frameworks not only deepen mechanistic understanding but also provide templates for structure-guided drug design — whether inhibiting telomerase in cancer or restoring function in aging-related telomeropathies. Caveats include the inherent challenge of capturing dynamic processes in static structural snapshots and the difficulty of reconstituting full human holoenzyme complexity in vitro.